Skip to Main Content

An official website of the United States government

About this Publication
Title
Changes in and Impact of the Death Review Process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Pubmed ID
26238119 (View this publication on the PubMed website)
Publication
Rev Recent Clin Trials. 2015; Volume 10 (Issue 3): Pages 206-11
Authors
Miller AB, Feld R, Fontana R, Gohagan JK, Jatoi I, Lawrence W, Miller A, ProroK PC, Rajput A, Sherman M, Welch G, Wright P, Yurgalevitch S, Albertsen P
Affiliations
  • Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, M5T 3M7, Canada. ab.miller@sympatico.ca.
Abstract

Death review was conducted for the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial to avoid the biases associated with causes of death entered on death certificates. An algorithm selected deaths for review. Records on diagnosis and terminal illness were perused in the coordinating center and by the chair of the death review committee (DRC). Identifying information and randomization arm was removed. Three reviewers independently determined the cause of death. Disagreement was resolved at a meeting of the DRC. This process was subsequently simplified. The cause of death was determined by one DRC member and compared to the death certificate. With agreement the case was finalized. When discordant, the records were sent to a second DRC member. If the reviewers agreed, the case was finalized. If not, a third member reviewed. If two of the three reviewers agreed, the case was sent back to the discordant reviewer. If the reviewer remained discordant the case was resolved by a conference call. Of the 4728 death reviews that were completed, the DRC confirmed the death certificate underlying cause for over 90%. Between 5% and 13% of the certified deaths were regarded as indirect causes of death, associated with the treatment of the ascertained cancer; differential for prostate cancer, 11% in the intervention arm and 6% in the control. Without review, between 1% and 6% of the deaths that occurred would not have been assigned to the relevant PLCO cancer. The DRC completed 76% of those requiring review before the process ceased.

Related CDAS Studies
Related CDAS Projects